Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome

  title={Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome},
  author={John S Kane and Alexander Charles Ford},
  journal={Expert Review of Gastroenterology \& Hepatology},
  pages={431 - 442}
  • J. Kane, A. Ford
  • Published 1 March 2016
  • Medicine
  • Expert Review of Gastroenterology & Hepatology
ABSTRACT Irritable bowel syndrome (IBS) is a chronic, functional bowel disorder characterized by abdominal pain or discomfort and altered bowel habit. The pathophysiology is unclear, but may include altered gut motility, visceral hypersensitivity, abnormal central pain processing, chronic low-grade intestinal inflammation, or disturbances in the gut microbiome. These etiological mechanisms, alongside environmental factors such as stress and anxiety, vary between individuals and represent… 
Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome
Eluxadoline showed a low rate of constipation development in IBS patients in comparison with known effects of other opioid receptor modulators, and its efficacy over placebo has been demonstrated in short- and long-term clinical studies in humans.
Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review
Current studies indicate that rifaximin induces only modest effects on the gut microbiota of patients with IBS-D, suggesting that the efficacy of rifaxin may involve other mechanisms, and further study is needed.
Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. The SEPD perspective.
  • I. Vera, F. J. Júdez
  • Medicine
    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
  • 2017
Eluxadoline provides, with advantage over the current standard of care, control of both stool consistency and abdominal pain, good tolerability in most cases, and improved quality of life, hence it deserves consideration when approaching a patient with this disorder.
Short-course Rifaximin therapy is effective and safe in patients with Diarrhea-Predominant Irritable Bowel Syndrome
A short course (2 weeks) of rifaximin effectively and safely improved GI symptoms and QOL in Chinese patients with IBS-D, however, it did not eradicate SIBO completely, indicating that rifaxIMin might not be closely associated with LHBT normalization and that an additional therapeutic mechanism of r Halifaximin is urgently needed.
Faecal calprotectin levels after rifaximin treatment in patients with irritable bowel syndrome with diarrhoea: A single-center prospective study.
  • E. Safwat, M. Salah, H. Hussein
  • Medicine
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  • 2020
Pharmacological and Clinical Treatment of Irritable Bowel Syndrome
An overview on drugs that are currently available for IBS therapy with regard to the type of the disease is provided and selected complementary and alternative (CAM) medicine methods that have been proven effective in clinical tests are introduced.
Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome
A short course of rifaximin improved GI symptoms and QOL in Chinese IBS-D patients whether they had SIBO or not, however, the efficacy could not be explained by the successful eradication of SIBO.
Irritable bowel syndrome and colonic diverticular disease: overlapping symptoms and overlapping therapeutic approaches
Although relationships between uncomplicated diverticular disease and IBS have been reexamined their status remains unclear, as yet, however, none of the newer concepts related to this relationship have led to new therapeutic approaches in IBS or diversionicular disease.
The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS)
  • E. Quigley
  • Medicine
    Journal of clinical medicine
  • 2018
Given the widespread interest in the gut microbiome in health and disease, reports of disordered enteric bacterial communities in IBS, and experimental data to indicate that components of the gut microbiota can influence brain morphology and function, this concept has been extended to encompass the microbiota-gut-brain axis.
Rifaximin: unique selective antibiotic for the treatment of gastrointestinal diseases
  • E. Plotnikova
  • Biology, Medicine
    Meditsinskiy sovet = Medical Council
  • 2021
The pharmacology and pharmacodynamics of rifaximin are presented, describing various actions beyond its antibacterial activity, such as altering virulence, preventing intestinal mucosal adhesion and bacterial translocation.


The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome
Whether the nonabsorbed antibiotic rifaximin is more effective than placebo in reducing symptoms in adults with IBS is determined.
Rifaximin therapy for patients with irritable bowel syndrome without constipation.
Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools.
Irritable Bowel Syndrome: A Clinical Review.
Central Sensitization (CS) would offer a way to conceptualize an integration of life experience and psychologic response into a biopsychosocial framework of pathophysiology, diagnosis and treatment of IBS.
Abnormal Intestinal Permeability in Subgroups of Diarrhea-Predominant Irritable Bowel Syndromes
Small intestinal permeability is frequently abnormal in diarrhea-predominant IBS, and those without a history of infectious onset appear to have a more severe defect.
Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome
An improvement in irritable bowel syndrome symptoms with diarrhea and abdominal pain being statistically significant after Bonferroni correction is revealed.
Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Patients given eluxadoline were significantly more likely to be clinical responders, based on a composite of improvement in abdominal pain and stool consistency, in a phase 2 study of the mixed μ-opioid receptor agonist/δ-opIOid receptor antagonist in patients with IBS-D.
Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.
Rifaximin alters the bacterial population in the ileum of rats, leading to a relative abundance of Lactobacillus, which prevents intestinal abnormalities and visceral hyperalgesia in response to chronic psychological stress.
High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome
  • J. Jolley
  • Medicine
    Clinical and experimental gastroenterology
  • 2011
Rifaximin 1200 mg/day for 10 days reduced gastrointestinal symptoms in patients with IBS and was well tolerated, and patients with incomplete symptom resolution may respond to increased doses of rifaxIMin.
Intestinal microbiota in functional bowel disorders: a Rome foundation report
A critical review of current hypotheses regarding the pathogenetic involvement of microbiota in FGID is provided and the results of microbiota-directed interventions are evaluated and clinical guidance on modulation of gut microbiota in IBS is provided.
Altered Colonic Bacterial Fermentation as a Potential Pathophysiological Factor in Irritable Bowel Syndrome
Colonic intraluminal pH is decreased, suggesting higher colonic fermentation, in IBS patients compared with HC, and total SCFA level in all IBS subjects was similar with that of HC.